These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3039718)

  • 21. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.
    Lobato ZI; Coupar BE; Gray CP; Lunt R; Andrew ME
    Vet Immunol Immunopathol; 1997 Nov; 59(3-4):293-309. PubMed ID: 9477479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the humoral response between sheep vaccinated with a killed-virus vaccine and those vaccinated with a modified-live virus vaccine against bluetongue virus serotype 17.
    Speiser KL; Schumaker BA; Cook WE; Cornish TE; Cammack KM; Miller MM
    J Am Vet Med Assoc; 2016 May; 248(9):1043-9. PubMed ID: 27074613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.
    Roy P; Bishop DH; LeBlois H; Erasmus BJ
    Vaccine; 1994 Jul; 12(9):805-11. PubMed ID: 7975859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a monoclonal antibody blocking ELISA for the detection of group-specific antibodies to bluetongue virus in experimental and field sera.
    Lunt RA; White JR; Blacksell SD
    J Gen Virol; 1988 Nov; 69 ( Pt 11)():2729-40. PubMed ID: 2846758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of virologic and serologic responses of lambs and calves infected with bluetongue virus serotype 10.
    Richards RG; MacLachlan NJ; Heidner HW; Fuller FJ
    Vet Microbiol; 1988 Dec; 18(3-4):233-42. PubMed ID: 2852871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A one-year follow-up of antibody response in cattle and sheep after vaccination with serotype 8- and serotype 1-inactivated BT vaccines.
    Zanella G; Bréard E; Sailleau C; Zientara S; Viarouge C; Durand B
    Transbound Emerg Dis; 2014 Oct; 61(5):473-6. PubMed ID: 23331382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing Montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage.
    Zhugunissov K; Bulatov Y; Taranov D; Yershebulov Z; Koshemetov Z; Zhunushov A; Renukaradhya GJ; Tabynov K; Abduraimov Y
    Vet Microbiol; 2018 Nov; 226():23-30. PubMed ID: 30389040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of different vaccination schemes used in sheep combining inactivated bluetongue vaccines against serotypes 4 and 8.
    Hilke J; Strobel H; Woelke S; Stoeter M; Voigt K; Grimm L; Meilwes J; Punsmann T; Blaha I; Salditt A; Rohn K; Bastian M; Ganter M
    Vaccine; 2019 Sep; 37(39):5844-5853. PubMed ID: 31431410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
    Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
    Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.
    Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of viral antigens in bluetongue virus-infected ovine tissues, using the peroxidase-antiperoxidase technique.
    Cherrington JM; Ghalib HW; Sawyer MM; Osburn BI
    Am J Vet Res; 1985 Nov; 46(11):2356-9. PubMed ID: 3000230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors associated with the occurrence of undesired effects in sheep and goats after field vaccination with modified-live vaccine against bluetongue virus serotypes 2, 4 and 16.
    Savini G; Cannas A; Casaccia C; Di Gialleonardo L; Leone A; Patta C; Nicolussi P
    Vet Microbiol; 2010 Nov; 146(1-2):44-50. PubMed ID: 20537822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies to bluetongue virus define two neutralizing epitopes and a hemagglutinating epitope.
    Mecham JO; Jochim MM
    Viral Immunol; 1990; 3(2):161-70. PubMed ID: 1694430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccines for bluetongue and other orbiviruses from a regulatory viewpoint.
    Strating A
    Prog Clin Biol Res; 1985; 178():627-9. PubMed ID: 2989911
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative analysis of cellular immune responses and cytokine levels in sheep experimentally infected with bluetongue virus serotype 1 and 8.
    Sánchez-Cordón PJ; Pérez de Diego AC; Gómez-Villamandos JC; Sánchez-Vizcaíno JM; Pleguezuelos FJ; Garfia B; del Carmen P; Pedrera M
    Vet Microbiol; 2015 May; 177(1-2):95-105. PubMed ID: 25769647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge.
    Wade-Evans AM; Romero CH; Mellor P; Takamatsu H; Anderson J; Thevasagayam J; Fleming MJ; Mertens PP; Black DN
    Virology; 1996 Jun; 220(1):227-31. PubMed ID: 8659119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of bluetongue viral antibodies in Louisiana goats.
    Fulton RW; Potter MT; Pearson NJ; Hagstad HV
    Am J Vet Res; 1981 Nov; 42(11):1985-6. PubMed ID: 6278995
    [No Abstract]   [Full Text] [Related]  

  • 40. An experimental inactivated vaccine against bluetongue.
    Parker J; Herniman KA; Gibbs EP; Sellers RF
    Vet Rec; 1975 Mar; 96(13):284-7. PubMed ID: 165609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.